Literature DB >> 24460316

ATF3 activates Stat3 phosphorylation through inhibition of p53 expression in skin cancer cells.

Zhen-Feng Hao1, Jun-Hong Ao, Jie Zhang, You-Ming Su, Rong-Ya Yang.   

Abstract

AIM: ATF3, a member of the ATF/CREB family of transcription factors, has been found to be selectively induced by calcineurin/NFAT inhibition and to enhance keratinocyte tumor formation, although the precise role of ATF3 in human skin cancer and possible mechanisms remain unknown.
METHODS: In this study, clinical analysis of 30 skin cancer patients and 30 normal donors revealed that ATF3 was accumulated in skin cancer tissues. Functional assays demonstrated that ATF3 significantly promoted skin cancer cell proliferation.
RESULTS: Mechanically, ATF3 activated Stat3 phosphorylation in skin cancer cell through regulation of p53 expression. Moreover, the promotion effect of ATF3 on skin cancer cell proliferation was dependent on the p53-Stat3 signaling cascade.
CONCLUSION: Together, the results indicate that ATF3 might promote skin cancer cell proliferation and enhance skin keratinocyte tumor development through inhibiting p53 expression and then activating Stat3 phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24460316     DOI: 10.7314/apjcp.2013.14.12.7439

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  10 in total

1.  Runx2, a target gene for activating transcription factor-3 in human breast cancer cells.

Authors:  M Gokulnath; N C Partridge; N Selvamurugan
Journal:  Tumour Biol       Date:  2014-11-08

2.  Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells.

Authors:  Zhen-Feng Hao; You-Ming Su; Cong-min Wang; Rong-Ya Yang
Journal:  Tumour Biol       Date:  2014-11-05

Review 3.  Emerging roles of activating transcription factor (ATF) family members in tumourigenesis and immunity: Implications in cancer immunotherapy.

Authors:  Meilin Chen; Yijun Liu; Yuqin Yang; Yanbing Qiu; Zhicheng Wang; Xiaoxu Li; Wenling Zhang
Journal:  Genes Dis       Date:  2021-06-03

4.  Activating transcription factor 3 promotes malignance of lung cancer cells in vitro.

Authors:  Xuebing Li; Xuexia Zhou; Yongwen Li; Lingling Zu; Hongli Pan; Boning Liu; Wang Shen; Yaguang Fan; Qinghua Zhou
Journal:  Thorac Cancer       Date:  2017-02-27       Impact factor: 3.500

5.  Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling.

Authors:  Dazhi Fu; Chunxiao Wang; Lei Yu; Rui Yu
Journal:  Cell Mol Biol Lett       Date:  2021-06-07       Impact factor: 5.787

6.  Expression and Function of HAX-1 in Human Cutaneous Squamous Cell Carcinoma.

Authors:  Xingyu Li; Tiejun Li; Bo You; Yin Shan; Si Shi; Xiaolei Cao; Li Qian
Journal:  J Cancer       Date:  2015-02-20       Impact factor: 4.207

7.  Comparison of P53 Intensity, Frequency and Size in Normal Skin Periphery of Squamous Cell Carcinoma, Basal Cell Carcinoma And Melanocytic Nevus in Persian Skin Type.

Authors:  Farahnaz Bidari Zerehpoosh; Soheila Nasiri; Sara Zahedifard; Shahram Sabeti
Journal:  Iran J Pathol       Date:  2017-08-30

8.  ATF3 Sustains IL-22-Induced STAT3 Phosphorylation to Maintain Mucosal Immunity Through Inhibiting Phosphatases.

Authors:  Doaa Glal; Janaki N Sudhakar; Hsueh-Han Lu; Ming-Che Liu; Hung-Yu Chiang; Yen-Chun Liu; Ching-Feng Cheng; Jr-Wen Shui
Journal:  Front Immunol       Date:  2018-11-05       Impact factor: 7.561

9.  Serum and Adipose Tissue mRNA Levels of ATF3 and FNDC5/Irisin in Colorectal Cancer Patients With or Without Obesity.

Authors:  Huijuan Zhu; Meijuan Liu; Nianrong Zhang; Hui Pan; Guole Lin; Naishi Li; Linjie Wang; Hongbo Yang; Kemin Yan; Fengying Gong
Journal:  Front Physiol       Date:  2018-09-10       Impact factor: 4.566

10.  Cardiac Fibroblast-Specific Activating Transcription Factor 3 Promotes Myocardial Repair after Myocardial Infarction.

Authors:  Yu-Lin Li; Wen-Jing Hao; Bo-Ya Chen; Jing Chen; Guo-Qi Li
Journal:  Chin Med J (Engl)       Date:  2018-10-05       Impact factor: 2.628

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.